Sunday November 19th, 2017
About Us  |  Employment Opportunities  |  Contact HRC
Home FoodDrugsBlood & BiologicsMedical DevicesImports & ExportsAnimal Food & DrugTobacco
{d3}

Prescription & OTC Drugs

If your company is sponsoring clinical trials, have you considered multi-regional trials and what you may need to do to ensure that your data is credible, reproducible and appropriate for use in targeted patient populations across the globe?

If you are a manufacturer and are sourcing raw materials from foreign locations, are you aware of new strategies FDA is considering for securing the integrity of the nation’s drug supply?

At Humphrey Regulatory Consulting (HRC), our consultants and regulatory scientists are extremely knowledgable about the implications of clinical development programs conducted both domestically and internationally, and can help sponsors and manufacturers with ensuring compliance while obtaining meaningful results.

We also assist sponsors, manufacturers, distributors and importers, by embracing the globalization of the pharmaceutical industry while providing strategies for ensuring that all material and products coming into the US market meet acceptable quality standards to support their commercialization.

Whether a US-based or foreign firm, sponsoring clinical or bioequivalence studies, or manufacturing API or finished dosage forms, HRC specializes in global product development and approval strategies and can help your company develop compliant strategies for:


NDAs, sNDAs, 505(b)(2)s:
   • GCP compliance and the conduct of both domestic and multi-regional development strategies for efficient trial design
   • Pre-IND and End-of-Phase II preparatory meetings with FDA and establishing consultations with foreign regulatory authorities
   • Preparation/manufacturing of trial materials
   • ANDAs
   • Product development strategies for the US, Latin America, China, Korea, and other Pacific-rim locations
   • GCP compliance for the conduct of bioequivalence studies
   • Evaluation of appropriate reference listed drug (RLD) in your development pipeline

Manufacturing:
   • cGMP compliance and audits
   • Personnel Training programs
   • Product eligibility for purchase under the WHO pre-qualification program and China's Essential Medicines List
   • Serialization strategies to comply with international packaging and labeling requirements
   • Preparing for Commercial Launch
   • Registration of facilities and products (NDC listing)
   • Advertising and Promotion support
   • REMS management

Copyright © 2017 Humphrey Regulatory Consulting Inc. All rights reserved.  |    |  Terms of Use  |  Privacy Policy

Editor Login